Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- US Chamber Raises Japan’s Pharma Policy as Unfair Trade Practice, Prods Federal Govt for Action
March 19, 2025
- MHLW to Investigate Pharmaceutical Ad Regulations in US, Europe
March 18, 2025
- MHLW Council OKs Public Knowledge Filing for Anaemetro’s Pediatric Use
March 17, 2025
- PMDA Reviewing Safety Risks of Paxlovid/Xtandi Concurrent Use
March 17, 2025
- MHLW Panel OKs List of “High-Priority” Vaccines, including Norovirus Jabs
March 14, 2025
- JPA Asks for Price Penalty for High-Cost Meds with Packaging Unaligned to Dosing
March 14, 2025
- Chuikyo to Discuss Potential Pricing Steps to Deal with Higher Costs of Japan-Made APIs
March 13, 2025
- MHLW to Extend NIP Period for MR Vaccines by 2 Years amid Shortage
March 13, 2025
- Chuikyo Rep Calls for Proper Use of Zepbound, Frets Expansion of Obesity Market
March 13, 2025
- Imdelltra, Balversa, 2 More New Drugs Skip March Listing
March 13, 2025
- Zepbound, Qalsody, and More New Drugs Set for Japan Listing on March 19
March 13, 2025
- MHLW to “Listen to Industry Opinions” in Policymaking around CEA: Minister
March 13, 2025
- CellCept Now Covered for Nephrotic Syndrome: MHLW
March 13, 2025
- Litfulo’s Price to Be Trimmed 3.8% in June after CEA
March 13, 2025
- Re-Priced Unprofitable Products Subject to Unit Price-Based Trades for 2 Years: MHLW
March 12, 2025
- Trerief and Nobelzin Newly Added to Elective Care Scheme; Allegra, Takepron Excluded
March 12, 2025
- Health Ministry Presents Proposal to Revise Priority Infectious Diseases
March 12, 2025
- Ishiba Hints at Reflecting Wage Hikes in Drug Pricing
March 11, 2025
- Stelara to Get 40.8% Price Cut on PMP Return, Januvia Over 26% in 2025 Revision
March 10, 2025
- Ishiba Flip-Flops on Copay Cap Hike, Drops Planned Raise in August
March 10, 2025
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…